Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Anemia 1

Interventions

Specimen Handling 71Magnetic Resonance Spectroscopy 55Biopsy 43pembrolizumab 25Carboplatin 25Radiation 24Radiotherapy 23Cyclophosphamide 23Nivolumab 21Paclitaxel 20Cisplatin 20olaparib 18Etoposide 18Doxorubicin 17X-Rays 16Vincristine 16Taxes 15Immunoglobulin G 15Disulfides 15Radiotherapy, Intensity-Modulated 14Leucovorin 14Dexamethasone 14Cytarabine 14Bevacizumab 14durvalumab 13Prednisone 13Platinum 131,2-diaminocyclohexaneplatinum II citrate 13Methotrexate 11Ipilimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pharmacogenomic Testing × 30 days × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡